176 related articles for article (PubMed ID: 32223936)
21. Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers.
Farago AF; Demetri GD
Future Oncol; 2020 Mar; 16(9):417-425. PubMed ID: 32129093
[TBL] [Abstract][Full Text] [Related]
22. Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer.
Federman N; McDermott R
Expert Rev Clin Pharmacol; 2019 Oct; 12(10):931-939. PubMed ID: 31469968
[No Abstract] [Full Text] [Related]
23. A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.
Drilon A; Nagasubramanian R; Blake JF; Ku N; Tuch BB; Ebata K; Smith S; Lauriault V; Kolakowski GR; Brandhuber BJ; Larsen PD; Bouhana KS; Winski SL; Hamor R; Wu WI; Parker A; Morales TH; Sullivan FX; DeWolf WE; Wollenberg LA; Gordon PR; Douglas-Lindsay DN; Scaltriti M; Benayed R; Raj S; Hanusch B; Schram AM; Jonsson P; Berger MF; Hechtman JF; Taylor BS; Andrews S; Rothenberg SM; Hyman DM
Cancer Discov; 2017 Sep; 7(9):963-972. PubMed ID: 28578312
[TBL] [Abstract][Full Text] [Related]
24. Rapid Clinical and Radiologic Responses With Larotrectinib Treatment in a Patient With TRK-Fusion-Positive Metastatic Lung Cancer.
Hochmair MJ; Setinek U; Krenbek D; Fazekas A; Illini O; Weinlinger C; Draxler H; Marcher M; Valipour A; Müllauer L; Beer L
Clin Lung Cancer; 2020 Mar; 21(2):e49-e53. PubMed ID: 31879191
[No Abstract] [Full Text] [Related]
25. Dramatic Responses Seen with TRK Inhibitor.
Cancer Discov; 2017 Aug; 7(8):787. PubMed ID: 28583910
[TBL] [Abstract][Full Text] [Related]
26. Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application.
Yan W; Lakkaniga NR; Carlomagno F; Santoro M; McDonald NQ; Lv F; Gunaganti N; Frett B; Li HY
J Med Chem; 2019 Feb; 62(4):1731-1760. PubMed ID: 30188734
[TBL] [Abstract][Full Text] [Related]
27. Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.
Menichincheri M; Ardini E; Magnaghi P; Avanzi N; Banfi P; Bossi R; Buffa L; Canevari G; Ceriani L; Colombo M; Corti L; Donati D; Fasolini M; Felder E; Fiorelli C; Fiorentini F; Galvani A; Isacchi A; Borgia AL; Marchionni C; Nesi M; Orrenius C; Panzeri A; Pesenti E; Rusconi L; Saccardo MB; Vanotti E; Perrone E; Orsini P
J Med Chem; 2016 Apr; 59(7):3392-408. PubMed ID: 27003761
[TBL] [Abstract][Full Text] [Related]
28. TRK Inhibitors: Clinical Development of Larotrectinib.
Bhangoo MS; Sigal D
Curr Oncol Rep; 2019 Feb; 21(2):14. PubMed ID: 30715603
[TBL] [Abstract][Full Text] [Related]
29. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
Drilon A; Siena S; Ou SI; Patel M; Ahn MJ; Lee J; Bauer TM; Farago AF; Wheler JJ; Liu SV; Doebele R; Giannetta L; Cerea G; Marrapese G; Schirru M; Amatu A; Bencardino K; Palmeri L; Sartore-Bianchi A; Vanzulli A; Cresta S; Damian S; Duca M; Ardini E; Li G; Christiansen J; Kowalski K; Johnson AD; Patel R; Luo D; Chow-Maneval E; Hornby Z; Multani PS; Shaw AT; De Braud FG
Cancer Discov; 2017 Apr; 7(4):400-409. PubMed ID: 28183697
[TBL] [Abstract][Full Text] [Related]
30. Tumour-agnostic drugs and future cancer treatment.
Børset M
Tidsskr Nor Laegeforen; 2019 Mar; 139(5):. PubMed ID: 30872821
[No Abstract] [Full Text] [Related]
31. Larotrectinib followed by selitrectinib in a novel
Goh XN; Seng MS; Loh AHP; Gupta A; Chang KTE; Iyer P
J Oncol Pharm Pract; 2021 Mar; 27(2):485-489. PubMed ID: 32693686
[TBL] [Abstract][Full Text] [Related]
32. How I treat
Lassen U
ESMO Open; 2019; 4(Suppl 2):e000612. PubMed ID: 31803506
[No Abstract] [Full Text] [Related]
33. [NTRK Fusions: A new way of treatment for gastro-intestinal tumor?].
Ouali K; Pellat A; Cohen R; Svrcek M; Penault-Llorca F; André T
Bull Cancer; 2020 Apr; 107(4):447-457. PubMed ID: 32067719
[TBL] [Abstract][Full Text] [Related]
34. Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies.
Taylor J; Pavlick D; Yoshimi A; Marcelus C; Chung SS; Hechtman JF; Benayed R; Cocco E; Durham BH; Bitner L; Inoue D; Chung YR; Mullaney K; Watts JM; Diamond EL; Albacker LA; Mughal TI; Ebata K; Tuch BB; Ku N; Scaltriti M; Roshal M; Arcila M; Ali S; Hyman DM; Park JH; Abdel-Wahab O
J Clin Invest; 2018 Aug; 128(9):3819-3825. PubMed ID: 29920189
[TBL] [Abstract][Full Text] [Related]
35. Larotrectinib in TRK fusion-positive pediatric B-cell acute lymphoblastic leukemia.
Schewe DM; Lenk L; Vogiatzi F; Winterberg D; Rademacher AV; Buchmann S; Henry D; Bergmann AK; Cario G; Cox MC
Blood Adv; 2019 Nov; 3(22):3499-3502. PubMed ID: 31725893
[TBL] [Abstract][Full Text] [Related]
36. Foretinib Overcomes Entrectinib Resistance Associated with the
Nishiyama A; Yamada T; Kita K; Wang R; Arai S; Fukuda K; Tanimoto A; Takeuchi S; Tange S; Tajima A; Furuya N; Kinoshita T; Yano S
Clin Cancer Res; 2018 May; 24(10):2357-2369. PubMed ID: 29463555
[No Abstract] [Full Text] [Related]
37. Acquired Resistance Is Oncogene and Drug Agnostic.
Doebele RC
Cancer Cell; 2019 Oct; 36(4):347-349. PubMed ID: 31614114
[TBL] [Abstract][Full Text] [Related]
38. Larotrectinib for the treatment of TRK fusion solid tumors.
Laetsch TW; Hawkins DS
Expert Rev Anticancer Ther; 2019 Jan; 19(1):1-10. PubMed ID: 30350734
[No Abstract] [Full Text] [Related]
39. Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in
Smith KM; Fagan PC; Pomari E; Germano G; Frasson C; Walsh C; Silverman I; Bonvini P; Li G
Mol Cancer Ther; 2018 Feb; 17(2):455-463. PubMed ID: 29237803
[TBL] [Abstract][Full Text] [Related]
40. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
